Research & Evidence
The 1% Treaty redirects $27.2 billion a year from weapons and military budgets. After incentives and operating costs, $21.7 billion funds 23.4 million pragmatic-trial participants a year.
GOVERNMENTS SPEND
THAN PUBLICLY FUNDED CLINICAL TRIALS
One percent produces $27.2 billion in annual treaty funding.
Pragmatic clinical trials
Treaty success rewards
Political incentives for adoption
Pragmatic trials use routine care and health records instead of building a separate research system. RECOVERY cost about $500 per participant. The capacity model uses $929.
The $929 figure drives the capacity model. The $41,000 figure shows the cost difference.
About 6,650 diseases have no effective treatment. At 15 first treatments a year, the backlog lasts 443 years.
Trial participation rises from 1.9 million to 23.4 million people a year. The model scales first treatments from 15 to 185 a year.
Model estimate
The model combines higher trial capacity with earlier access to treatments.
Across future generations during the modeled 212-year acceleration in treatment availability.
Years of healthy life restored by preventing disability and early death.
SIPRI spending total used to calculate the treaty funding.
View sourceGovernment-funded clinical-trial spending used in the comparison chart.
View sourceObserved per-patient cost from a large pragmatic clinical trial.
View sourceThe $929 per-patient estimate used to calculate trial capacity.
View sourceMedian per-patient benchmark used only for the cost comparison.
View sourceThe 6,650-disease backlog used in the eradication timeline.
View calculationCurrent rate used to calculate the 443-year timeline.
View sourceCalculation behind the cumulative deaths and DALYs averted estimates.
View calculation